Replimune Group Inc (REPL NASDAQ) stock market data APIs
$8.0038
-0.03(-0.4%)
as of February 13, 2026
Try our APIs with
free plan!
Replimune Group Inc Financial Data Overview
Price chart is built with
Anychart
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Prev. Close
8.0038
Open
7.9707
High
8.4333
Low
7.9415
52 wk Range
2.68-14.7952
Market Cap
658 M
Shares Outstanding
82 573 K
EPS
-0.77
Beta
0.747
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Replimune Group Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Replimune Group Inc data using free add-ons & libraries
Get Replimune Group Inc Fundamental Data
Replimune Group Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -318 880 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-11
- EPS/Forecast: -0.7649
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Replimune Group Inc News
New
Replimune Group GAAP EPS of -$0.77 beats by $0.01
* Replimune Group press release [https://seekingalpha.com/pr/20385487-replimune-reports-fiscal-third-quarter-2026-financial-results-and-provides-corporate-update] (REPL [https://seekingalpha.com/sym...
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
April 10, 2026 Target Action Date for RP1 in Advanced Melanoma WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Alto Neuroscience, Inc. (NYSE: ANRO), Atkore Inc. ...
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In October, the FDA accepted the resubmission of the biologics license application...
Get Replimune Group Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
